KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Equity for 15 consecutive years, with 1.15% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 6.0% to 1.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.15% through Dec 2025, up 6.0% year-over-year, with the annual reading at 1.54% for FY2025, 45.0% down from the prior year.
  • Return on Equity for Q4 2025 was 1.15% at Halozyme Therapeutics, down from 1.42% in the prior quarter.
  • The five-year high for Return on Equity was 2.44% in Q2 2021, with the low at 1.06% in Q3 2024.
  • Average Return on Equity over 5 years is 1.56%, with a median of 1.47% recorded in 2021.
  • The sharpest move saw Return on Equity soared 293bps in 2021, then crashed -129bps in 2025.
  • Over 5 years, Return on Equity stood at 1.68% in 2021, then dropped by -10bps to 1.52% in 2022, then rose by 12bps to 1.69% in 2023, then crashed by -36bps to 1.09% in 2024, then increased by 5bps to 1.15% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 1.15%, 1.42%, and 1.37% for Q4 2025, Q3 2025, and Q2 2025 respectively.